Supplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States

Supplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States

<p>Supplementary Table S8</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Laura E. Stevens (14961009) (author)
Autres auteurs:	Guillermo Peluffo (14961012) (author), Xintao Qiu (14958882) (author), Daniel Temko (14961015) (author), Anne Fassl (14961018) (author), Zheqi Li (14961021) (author), Anne Trinh (14961024) (author), Marco Seehawer (14961027) (author), Bojana Jovanović (14961030) (author), Maša Alečković (14961033) (author), Callahan M. Wilde (14961036) (author), Renee C. Geck (14961039) (author), Shaokun Shu (14961042) (author), Natalie L. Kingston (14961045) (author), Nicholas W. Harper (14937782) (author), Vanessa Almendro (14961048) (author), Alanna L. Pyke (14961051) (author), Shawn B. Egri (14961054) (author), Malvina Papanastasiou (14961057) (author), Kendell Clement (14961060) (author), Ningxuan Zhou (14961063) (author), Sarah Walker (14961066) (author), Jacqueline Salas (14961069) (author), So Yeon Park (14961072) (author), David A. Frank (14961075) (author), Alexander Meissner (14961078) (author), Jacob D. Jaffe (14961081) (author), Piotr Sicinski (14961084) (author), Alex Toker (14961087) (author), Franziska Michor (14961090) (author), Henry W. Long (14947498) (author), Beth A. Overmoyer (14961093) (author), Kornelia Polyak (14961096) (author)
Publié:	2025
Sujets:	Cancer Tumor Biology Therapeutic Research and Development Breast Cancer Drug Resistance Tumor Heterogeneity
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Supplementary Table S1 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
par: Laura E. Stevens (14961009)
Publié: (2025)

Supplementary Table S2 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
par: Laura E. Stevens (14961009)
Publié: (2025)

Supplementary Table S3 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
par: Laura E. Stevens (14961009)
Publié: (2025)

Supplementary Table S4 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
par: Laura E. Stevens (14961009)
Publié: (2025)

Supplementary Table S5 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
par: Laura E. Stevens (14961009)
Publié: (2025)

Supplementary Table S6 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
par: Laura E. Stevens (14961009)
Publié: (2025)

Supplementary Table S7 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
par: Laura E. Stevens (14961009)
Publié: (2025)

Supplementary Table S9 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
par: Laura E. Stevens (14961009)
Publié: (2025)

Supplementary Table 8_Genes identified by classification analysis in pro vs non metastatic clones from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
par: Niccolò Roda (16437288)
Publié: (2025)

Supplementary Table 3_Clonal distribution analysis from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
par: Niccolò Roda (16437288)
Publié: (2025)

Supplementary Table 10_Pro metastatic pathways identified by classification analysis from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
par: Niccolò Roda (16437288)
Publié: (2025)

Supplementary Table 1_Primer and shRNA sequences_PCR cycles_Mycoplasma testing from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
par: Niccolò Roda (16437288)
Publié: (2025)

Supplementary Table 2_Predictive power of genes and signatures_Patient cohorts GEO accession number from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
par: Niccolò Roda (16437288)
Publié: (2025)

Supplementary Table 6_Gene modules analysis_GO and curated pathways associated to gene modules from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
par: Niccolò Roda (16437288)
Publié: (2025)

Supplementary Table 9_Pro metastatic pathways identified by differential expression singlePT setting from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
par: Niccolò Roda (16437288)
Publié: (2025)

Supplementary Table 7_Genes identified by differential expression analysis in pro vs non metastatic clones from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
par: Niccolò Roda (16437288)
Publié: (2025)

Supplementary Table 4_Marker genes all and some per cluster_GO and curated pathways per cluster from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
par: Niccolò Roda (16437288)
Publié: (2025)

Supplementary Table 5_Marker genes all and some per cluster no cell cycle_GO and curated pathways per cluster no cell cycle from A Rare Subset of Primary Tumor Cells with Concomitant Hyperactivation of Extracellular Matrix Remodeling and dsRNA-IFN1 Signaling Metastasizes in Breast Cancer
par: Niccolò Roda (16437288)
Publié: (2025)

Supplemental Figure S8 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
par: Jennifer L. Cotton (17315204)
Publié: (2025)

Supplementary Data from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
par: Junko Tsuji (15051410)
Publié: (2025)

Supplementary Video from Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma
par: Laura Privitera (16015972)
Publié: (2025)

Supplementary File 1 from Spatial Transcriptomic Analysis of a Diverse Patient Cohort Reveals a Conserved Architecture in Triple-Negative Breast Cancer
par: Rania Bassiouni (14963190)
Publié: (2025)

Supplementary File 2 from Spatial Transcriptomic Analysis of a Diverse Patient Cohort Reveals a Conserved Architecture in Triple-Negative Breast Cancer
par: Rania Bassiouni (14963190)
Publié: (2025)

Figure S1 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
par: Alexander J. Cole (14971167)
Publié: (2025)

Figure S2 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
par: Alexander J. Cole (14971167)
Publié: (2025)

Figure S3 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
par: Alexander J. Cole (14971167)
Publié: (2025)

Figure S4 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
par: Alexander J. Cole (14971167)
Publié: (2025)

Figure S5 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
par: Alexander J. Cole (14971167)
Publié: (2025)

Supplementary Tables S1-S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
par: Axel Stenmark Tullberg (15029928)
Publié: (2025)

Supplemental Figure S1 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
par: Jennifer L. Cotton (17315204)
Publié: (2025)

Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
par: Jennifer L. Cotton (17315204)
Publié: (2025)

Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
par: Jennifer L. Cotton (17315204)
Publié: (2025)

Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
par: Jennifer L. Cotton (17315204)
Publié: (2025)

Supplemental Figure S5 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
par: Jennifer L. Cotton (17315204)
Publié: (2025)

Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
par: Jennifer L. Cotton (17315204)
Publié: (2025)

Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
par: Jennifer L. Cotton (17315204)
Publié: (2025)

Supplemental Tables 1 - 12 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
par: Jennifer L. Cotton (17315204)
Publié: (2025)

Supplementary Figure 8 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
par: Patrizia Mondello (15045002)
Publié: (2025)

Image 2_Immune-related RELT drives clear cell renal cell carcinoma progression through JAK/STAT signaling pathway activation.tiff
par: Yini Wang (410389)
Publié: (2025)

Image 1_Immune-related RELT drives clear cell renal cell carcinoma progression through JAK/STAT signaling pathway activation.tiff
par: Yini Wang (410389)
Publié: (2025)

Cannot write session to /tmp/vufind_sessions/sess_g0jmkf7ucg8dtda8id8gfef530